New hope for tough colon cancer: combo therapy targets BRAF mutation
NCT ID NCT07229846
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new immunotherapy drug (aipalolitovorelizumab) combined with standard chemotherapy and bevacizumab in 30 people with metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR type. The goal is to see if the combination shrinks tumors and controls the disease longer. Participants will receive the drugs intravenously and orally in cycles, followed by maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- aipalolitovorelizumab (QL1706) combined with bevacizumab and chemotherapy (oxaliplatin, irinotecan, fluorouracil, capecitabine)
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with a hard-to-treat form of colorectal cancer that has spread.
- What could go wrong
- This is a small, early-phase study with only 30 participants and no comparison group, so results may not apply broadly. The combination therapy may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hosptital
Harbin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?